Published in Virulence on August 19, 2013
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill. Physiol Rev (2015) 1.20
The future of murine sepsis and trauma research models. J Leukoc Biol (2015) 1.04
Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect. Toxins (Basel) (2013) 0.98
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci U S A (2015) 0.96
Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes. Am J Respir Crit Care Med (2014) 0.94
Use of Biotelemetry to Define Physiology-Based Deterioration Thresholds in a Murine Cecal Ligation and Puncture Model of Sepsis. Crit Care Med (2016) 0.88
Intestine-specific deletion of microsomal triglyceride transfer protein increases mortality in aged mice. PLoS One (2014) 0.86
Could Biomarkers Direct Therapy for the Septic Patient? J Pharmacol Exp Ther (2016) 0.84
Why do they die? Comparison of selected aspects of organ injury and dysfunction in mice surviving and dying in acute abdominal sepsis. Intensive Care Med Exp (2015) 0.82
Tissue-type Plasminogen Activator Regulates Macrophage Activation and Innate Immunity. Blood (2017) 0.81
CD1d- and MR1-Restricted T Cells in Sepsis. Front Immunol (2015) 0.81
Paeonol protects endotoxin-induced acute kidney injury: potential mechanism of inhibiting TLR4-NF-κB signal pathway. Oncotarget (2016) 0.80
HMGB1 as a drug target in staphylococcal pneumonia. Crit Care (2014) 0.79
The role of speckle tracking echocardiography in assessment of lipopolysaccharide-induced myocardial dysfunction in mice. J Thorac Dis (2015) 0.77
Current knowledge and future directions of TLR and NOD signaling in sepsis. Mil Med Res (2015) 0.77
IL-15 Enables Septic Shock by Maintaining NK Cell Integrity and Function. J Immunol (2016) 0.76
Early severe impairment of hematopoietic stem and progenitor cells from the bone marrow caused by CLP sepsis and endotoxemia in a humanized mice model. Stem Cell Res Ther (2015) 0.76
The current understanding of sepsis and research priorities for the future. Virulence (2013) 0.76
A Systematic Review of Rhubarb (a Traditional Chinese Medicine) Used for the Treatment of Experimental Sepsis. Evid Based Complement Alternat Med (2015) 0.76
Current Murine Models of Sepsis. Surg Infect (Larchmt) (2016) 0.75
Acute kidney injury and inflammatory response of sepsis following cecal ligation and puncture in d-galactose-induced aging rats. Clin Interv Aging (2017) 0.75
Expectations for methodology and translation of animal research: a survey of health care workers. BMC Med Ethics (2015) 0.75
Mass spectrometry for the discovery of biomarkers of sepsis. Mol Biosyst (2017) 0.75
Getting older can be exhausting. Crit Care (2014) 0.75
Inflammatory Response in Preterm and Very Preterm Newborns with Sepsis. Mediators Inflamm (2016) 0.75
Reducing Animal Use with a Biotelemetry-Enhanced Murine Model of Sepsis. Sci Rep (2017) 0.75
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther (2017) 0.75
Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia. Intensive Care Med Exp (2017) 0.75
The ten barriers for translation of animal data on AKI to the clinical setting. Intensive Care Med (2017) 0.75
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 16.37
Hydrocortisone therapy for patients with septic shock. N Engl J Med (2008) 15.85
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med (2012) 9.19
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 5.86
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet (2007) 5.23
Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med (1998) 5.22
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med (1997) 4.98
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med (2009) 4.98
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 4.54
Anti-endotoxin monoclonal antibodies. N Engl J Med (1992) 4.39
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med (2004) 4.24
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 4.05
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med (1987) 3.89
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 3.78
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Animal models of sepsis and shock: a review and lessons learned. Shock (1998) 3.65
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med (2004) 3.61
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med (1999) 3.20
Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med (2005) 3.09
Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med (1994) 3.09
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med (1993) 2.84
Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med (1993) 2.71
Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest (2009) 2.71
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 2.66
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med (2001) 2.56
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med (1995) 2.48
Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages. J Leukoc Biol (2009) 2.45
The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med (1984) 2.37
Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol (1992) 2.32
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 2.31
Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol (2009) 2.27
Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int (2003) 2.15
A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med (1991) 2.14
Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med (1998) 2.12
E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA (2000) 2.07
A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med (2002) 2.05
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest (1993) 2.00
Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med (2009) 1.99
Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med (2003) 1.98
LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol (2011) 1.95
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med (1998) 1.90
Laboratory models of sepsis and septic shock. J Surg Res (1990) 1.90
Genetic factors in leucocyte responses to endotoxin: further studies in mice. J Immunol (1969) 1.89
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 1.88
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med (2009) 1.82
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med (2004) 1.80
BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. I. In vivo studies. J Immunol (1980) 1.74
INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med (1996) 1.73
Resilience to bacterial infection: difference between species could be due to proteins in serum. J Infect Dis (2010) 1.73
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med (2011) 1.65
A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA (1993) 1.59
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest (1992) 1.58
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med (2013) 1.58
The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med (2001) 1.57
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med (2003) 1.53
Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med (2003) 1.45
Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo. Infect Immun (1976) 1.44
Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol (2009) 1.43
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med (2010) 1.42
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med (2001) 1.41
Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Crit Care Med (2001) 1.40
Rodent models of intra-abdominal infection. Shock (2005) 1.38
Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest (1993) 1.35
Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol (1995) 1.27
Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol (2007) 1.24
Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med (1994) 1.22
Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Physiol (2004) 1.17
Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med (1994) 1.13
Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med (2006) 1.11
Lipid A receptor TLR4-mediated signaling pathways. Adv Exp Med Biol (2010) 1.10
Scavenger receptor class a plays a central role in mediating mortality and the development of the pro-inflammatory phenotype in polymicrobial sepsis. PLoS Pathog (2012) 1.10
Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock (2006) 1.09
Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ (2010) 1.09
Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann Surg (1981) 1.08
Of men, not mice. Nat Med (2013) 1.06
Animal models of sepsis and its complications. Kidney Int (2008) 1.05
Animal models of sepsis. Crit Care Clin (2009) 1.04
Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg (2006) 1.02
Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother (1995) 1.02
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol (1996) 0.94
Species differences in Kupffer cells and endotoxin sensitivity. Infect Immun (1984) 0.93